Request Trial
tobias-wuttke_bardehle-pagenberg_8827_810
10 January 2023Muireann Bolger

Bardehle Pagenberg boosts litigation team with senior hire

German IP specialist gears up for UPC with experienced partner | Patent litigator previously led practice at IP boutique Meissner Bolte.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026   Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.
Biotech
Illumina ordered to recall products after German patent ruling
16 July 2026   A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.
Careers
Goodwin launches San Diego office with senior life sciences hire
16 July 2026   A high-profile hire will co-chair the firm's new office, bringing experience across biotech, therapeutics, genomics, diagnostics, and medical devices.


Editor's picks

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

Editor's picks

Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

Why is 2026 already a record year for M&A activity?
Illumina ordered to recall products after German patent ruling
Goodwin launches San Diego office with senior life sciences hire
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
IP Federation elects Philips licensing leader as new president
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen